History of the Research Effort
The Georgia Comprehensive Sickle Cell Center at Grady Health System, Atlanta, Georgia
Sickle cell disease is one of the most common genetic diseases in the United States, affecting one out of four hundred African Americans. This population is usually undeserved with a lack of specialty care available in the communities where the disease is prevalent. The disease causes recurrent pain episodes, increased infections and other complications requiring emergency medical intervention. Prior to 1984, patients presenting with uncomplicated sickle cell pain crisis were seen in the Grady Memorial Hospital Emergency Care Center and other Atlanta emergency rooms. With an excess of a quarter of a million patients in the Grady ER annually, sickle cell patients were often placed low on triage lists. Evaluation procedures were erratic and continuity of care was usually absent.
For this reason, an intense lobbying effort was led by the Sickle Cell Patient/Parent Group, Grady hospital administration and medical staff convinced members of the Georgia General Assembly of the need for a specialized clinic in the State of Georgia. In 1984, the Georgia General Assembly provided the original state grant of $550,000 to Grady Memorial Hospital to fund a 24-hour comprehensive acute care, Sickle Cell Center. The goals of the Center were to provide 24-hour acute care in a designated area with a dedicated staff, health care consultation, research new treatments, education and support services to residents of the state of Georgia with sickle cell syndromes. Pediatric and Adult Health Maintenance Appointment clinics deliver primary care to this population with the same staff and facilities. Center staff also visit inpatients with sickle syndromes on a daily basis to assist in management of specific problems and to maintain continuity of care. A number of group and individual counseling services are provided. Job training is provided for patients on site in a unique multimedia training room. The combination of these acute, primary care, and health maintenance services provide for an uncommon mix that has proven to serve the patient population in a very cost-effective manner. The program provides a wellness model for treatment of patients with a severe chronic disease, providing a practical solution to many problems faced in modern health care delivery.
Having established the clinic on this foundation, during the past 14 years the Center has grown in patient numbers, expanded its scope of services, and become an international leader in the care of sickle cell patients. This has occurred through the development of clinical guidelines that were first published and distributed world wide in 1991 and are now available on the World Wide Web for all providers to access. An extensive computerized patient database was developed to help track clinical care, costs and utilization of services. Computer based multimedia teaching materials about sickle cell disease were developed and offered to patients in a dedicated multimedia teaching center. Educational conferences are provided annually to update health care providers about the latest in sickle cell treatment. This educational material is captured in video and in CD-ROM format for international distribution.
The clinical success of the center, led by Dr. James Eckman, with a dedicated staff of hematologists, physician assistants, nurse practitioners, nurses, clinic assistants, social workers and clinical nurse specialists in psychiatry, allowed the staff to apply for Federal research funding. In 1993, The National Institutes of Health awarded Dr. Eckman, Emory University, and the Sickle Cell Center $7 million over five years in research funding for projects to discover new treatments and prevention of complications. From this research grant, we are now the leading center with five successful transplants of the fifty now transplanted in the twenty-five centers providing bone marrow transplants to cure sickle cell disease in the United States and Europe. The first unrelated cord blood stem cell transplant in the world for sickle cell disease was performed on one of our patients, who is still in the monitoring phase. New treatments were studied such as concentrated fish oil, or N3 fatty acids, that prevent pain events with little or no side effects. Over a one year period ten adult patients were randomized to receive the fish oil or the control substance, olive oil. Those receiving the fish oil had a 50% reduction in pain episodes when compared to the control group. This study also demonstrated the platelet activation and procoagulant activity in sickle cell patients redefining the role of thrombosis in sickle complications.
New psychosocial interventions involving family teaching and testing were established. Twenty five families completed a ten week educational intervention with nineteen families as controls. It was documented with pre and post test evaluations that the level of education about sickle cell disease improved with the intervention. One hunded and fifteen children were evalusted with extensive neurocognitive and psycological tests demonstrating a bidirectional interaction with the mothers’ coping correlating both to the childrens’ adaptation and the severity of disease. New patient and professional educational materials on computer based CD-ROM and Internet technology was developed.
Fifty-three sickle cell patients and seventeen controls were evaluated for kidney damage. The cause of damage in sickle cell disease was characterized as a loss of permselectivity and ultrafiltration capacity. Mirco-albinuria is an early detection test that can alert clinicians to this problem. This study determined that the prevalence of glomerular damage may be as high as 60% in adults with sickle cell disease. Preventive use of ACE inhibitors to prevent progressive renal disease is currently being studied.
Engineers at Georgia Tech, describing the causes and possible interventions, studied sickle red blood cell adhesion to blood vessel walls. Four major pathways of adherence have been characterized under flow conditions. The engineers have delveloped a cone and plate adhesion apparatus that simulates flow conditions inside blood vessels. They monitor sickle red cell adhesion to endothelial cells and have monitored the effect of nonionic poloxamer surfactant in blocking adhesion. This will help guide future therapy targeted at reducing sickle red cell adherance which may provide clinically useful treatment for acute complications.
The Center participated in the national multicenter study of the preventive drug hydroxiurea, now the only FDA approved therapy for preventing sickle cell pain events. Hydroxyurea was found to reduce pain episodes by one-half, the need for inpatient admission by one-half, and the need for transfused blood by one-half.
Dr. Eckman has championed newborn screening for sickle cell. This has saved the lives of many sickle cell children who would have died from pneumococcal sepsis if timely preventive penicillin was not started. It was through his efforts that Georgia instituted universal mandatory sickle cell screening for newborns in October of 1998.
The Center was one of the leading research facilities for the landmark transcranial doppler (TCD) ultrasound study to detect sickle cell children at high risk for strokes. One hundred and seventy children were screened, twenty-two were found to be at high risk, sixteen parents agreed to enter the protocol of monthly transfusion or standard therapy. This study clearly documented the benefit of chronic transfusion to prevent first stroke in these high risk children.
The Sickle Cell Center is an experiment in itself as a new model for chronic disease management. The computerized patient database has tracked the clinic population over several years. Over the last ten years, the annual cost of treating adult patients has been reduced by over two-thirds by reducing the need for hospitalization and increasing the compliance with health maintenance. The multidisciplinary team, the case management, the role of specialists acting as the primary care givers has created these beneficial trends. The aggressive treatment of pain events by the same clinic staff allows 80% of the patients with pain to return home without inpatient admission.
Improved Health Care Reduces Costs for Treatment
Year Outpatient Visits Admissions/100 Patient Years Cost/Active Adult
- 1985 1,134 215 $15,932
- 1996 2,032 83 $4,981
Currently, the Center is investigating the use of inhaled nitric oxide for treating pain episodes, a new pain meter for assessing pain in four dimensions over time, a therapeutic intervention to prevent kidney damage, and a teen intervention group. A unique vocational rehabilitation program is underway to train sickle cell patients in the Center’s multimedia center. Three classes of four patients each have graduated from a six week training course in photo processing. This program is one of the first hospital based vocational rehabilitation training program funded by the State of Georgia. The Sickle Cell Center has partnered with several Atlanta institutions to form The Atlanta Sickle Cell Consortium. This partnership will provide the best possible care and the latest advances for sickle cell care. The attached list represents the publications and presentations generated from the research.
Research Publications
• Flores L, Buchanan I, Arnelle D, Camp VM, Kutner M, Faraj BA, Eckman JR, Ragab A: Pyridoxal-5′- phosphate levels in children with sickle cell disease. Amer J Pediatr Hematol Oncol 10:236-240, 1988.
• Barrett DH, Wisotzek IE, Abel GG, Rouleau JL, Platt AF, Pollard WE, Eckman JR: Assessment of psychosocial functioning of sickle cell patients. Southern Med J 81:745-750, 1988.
• Allon M, Lawson L, Eckman JR, Delaney V, Bourke E: The effects of nonsteroidal anti-inflammatory drugs on renal function in sickle cell anemia. Kidney Int 34:500-506, 1988.
• Bishop AR, Roberson J, Eckman JR, Fleming LL: Total hip arthroplasty in patients who have sickle hemoglobinopathy. J Bone and Joint Surg Am 70a:853-855, 1988.
• Eckman JR: Sickle cell anemia: Pathophysiology and preventive treatment. Emory Univ J Med 2:140-146, 1988.
• Platt AP, Eckman JR: Management of pain in sickle cell anemia patients. J Amer Acad Phys Assist 2:104-113, 1989.
• Harris MS, Eckman JR: Georgia’s experience with newborn screening – 1981 – 1985. Pediatrics 83:858-860, 1989.
• Eckman JR, Kinney TR, Harris MS: Newborn for hemoglobinopathies: Facilitation by a TASCS Force. Ann New York Acad Sci 565:376-378, 1989.
• Ba’albaki HA, Eckman JR, Ghazzal ZMB, Felner JM, Schlant RC: Sickle cell disease and the cardiovascular system. Emory Univ J Med 3:163-171, 1989.
• Eckman JR, Harris MS, Kinney TR: Facilitation of newborn screening for hemoglobinopathies in the Southeastern United States by a TASCS Force. Proceedings of the 7th National Neonatal Screening Symposium, HB Branford, WH Hannon, BL Therrell, eds. Association of State and Laboratory Directors, Washington D.C., 1989, pp. 146-151.
• Oyesiku NM, Eckman JR, Barrow DL, Tindall SC, Colohan ART: Intracranial aneurysms in sickle cell anemia: Clinical features and pathogenesis. J Neurosurg 75:356-363, 1991.
• Eckman JR: Orderly approach to evaluation and treatment of anemia. Emory Univ J Med 5:80-90, 1991.
• Lane PA, Eckman JR: Cost-effectiveness of neonatal screening for sickle cell disease. Letter. J Pediatr 120:162-163, 1992.
• Therrell BL, Panny SR, Davidson A, Eckman JR, Hannon WH, Henson MA, Hillard M, Kling S, Levy HL, Meaney FJ, McCabe ERB, Mordaunt V, Pass K, Shapira E, Tuerck J: U.S. Newborn Screening System Guidelines: Statement of the Council of Regional Networks for Genetic Services. Prepared by the CORN Newborn Screening Committee, Council of Regional Networks for Genetic Services. Screening 1:135-147, 1992.
• Brittain HA, Eckman JR, Wick TM: Sickle erythrocyte adhesion to large vessel and microvascular endothelium under physiologic flow is qualitatively different. J Lab Clin Med 120:538-545, 1992.
• Wick TM, Brittain HA, Howard R, Eckman JR: Thrombospondin from activated platelets promotes sickle erythrocyte adhesion to human microvascular endothelial cells via CD36 and integrin receptors. In Vascular Endothelium: Physiologic Basis of Clinical Problems II. J. Catravas, A. Callow, N. Gillis, U. Ryan, A. Mantovani, and M. Yacoub, eds., Plenum, New York, pp. 213-214, 1993.
• Brown RT, Armstrong FD, Eckman JR: Neurocognitive aspects of pediatric sickle cell disease. J Learning Disabilities 26:33-45, 1993.
• Papadea C, Abbott K, Platt AF, Eckman JR: Comparison of abnormal hemoglobins for newborn screening using liquid and dried blood. Proceedings of the 8th National Neonatal Screening And XXI Birth Defects Symposium. KA Pass, ed. ASTPHLD. New York. 1991. pp. 114-119.
• Brown RT, Buchanan I, Doepke K, Eckman JR, Baldwin KC, Goonan B, Schoenherr S: Cognitive and academic functioning in children with sickle cell disease, J. Clin. Child Psychol. 22:207-218, 1993.
• Eckman JR: On sixty years of observation and interpretation in a single disease. Editorial on Dr. L.W. Diggs. South Med J 86:480-482, 1993.
• Brittain HA, Eckman JR, Howard RJ, Wick TM: Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: A potential role for platelet activation in sickle cell vaso-occlusion. Blood 81:2137-2143, 1993.
• Brown RT, Kaslow NJ, Doepke, KJ, Buchanan I, Eckman, JR, Baldwin K, Goonan MA: Psychosocial and family functioning in children with sickle cell syndrome and their mothers. J Am Child Adolesc Psychiatr 32:545-553, 1993.
• Swerlick RA, Eckman JR, Kumar A, Jeilter M, Wick TM: Reticulocytes from patients with sickle cell anemia express the a4/b1 integrin complex and bind to TNFa stimulated endothelial cells via a VCAM-1 – a4/b1 dependent mechanism. Blood 82:1891-1899, 1993.
• Hassell KL, Eckman JR, Lane PA: Acute multi-organ failure syndrome: A potential catastrophic complication of severe sickle pain episodes. Amer J Med 96:155-162, 1994.
• Papadea C, Eckman JR, Kuenhert R, Platt AF: Comparison of cord blood and dried blood spots for newborn hemoglobinopathy screening: Laboratory and programmatic issues. Pediatrics 93:427-432, 1994.
• Goonan B, Goonan L, Brown RT, Buchanan I, Eckman J: Sustained attention and inhibitory control in children with sickle cell syndrome. Arch Clin Neuropsychol 9:89-104, 1994.
• Wethers DL, Koshy M, Steinberg, MH, Phillips G, Siegel RS, Eckman JR, Prchal JT: Accelerated healing of chronic sickle-cell leg ulcers treated with RGD peptide matrix. Blood 84:1775-1779, 1994.
• Sharpe, JN, Brown RT, Thomson NJ, Eckman JR: Predictors of coping with pain in mothers and their children with sickle cell syndrome. J Am Acad Child Adolesc Psychiatry 33:1246-55, 1994.
• Stern MA, Eckman J, Offermann, MK: Aplastic anemia after exposure to burning oil. N Engl J Med 331:58, 1994.
• Brown RT, Eckman J, Baldwin K, Buchanan I, Dingle AD: Protective aspects of adaptive behavior in children with sickle cell syndromes. Children Health Care 24:205-222, 1995.
• Smolinski PA, Offermann MK, Eckman JR, Wick TM: Double-stranded RNA induces sickle erythrocyte adherence to endothelium: A potential role for viral infection in vaso-occlusive pain episodes in sickle cell anemia. Blood 85:2945-2950, 1995.
• Vichinsky EP, Haberkern CM, Neumayr L, et al: A comparison of conservative and aggressive transfusion regimens in the periooperative management of sickle cell disease. N Engl J Med 333:206-13, 1995.
• Meaney FJ, Kinney S, Kling S, Landenburger G, Panny S, Schwartz M, Heidenreich R, Therrell BL, Brokopp C, Eckman J, et al: Assessing genetic risks-implications for health and social policy: response from the newborn screening committee of the council of regional networks for genetic services. Screening. 4:247-249, 1996.
• Dumars KW, Boehm C, Eckman JR, Giardina PJ, Lane PA, Shafer FE: Practical guide to the diagnosis of thalassemia. Am J Med Genetics. 62:29-37, 1996.
• Wick TM, Eckman JR: Molecular basis of sickle cell-endothelial interactions. Curr Opinion Hematol. Current Opinion Hematol 3:118-124, 1996.
• Therrell BL, Hannon WH, Pass KA, Lorey F, Brokopp C, Eckman J, et al: Guidelines for the retention, storage, and use of residual dried blood spot samples after newborn screening analysis: statement of the Council of Regional Networks for Genetic Services. Biochem Molecular Med 57:116-124, 1996.
• Walters MC, Patience M, Leisenring W, Eckman JR, et al: Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 2:100-104, 1996.
• Walters MC, Patience M, Leisenring W, Eckman JR, et al: Bone marrow transplantation for sickle cell disease. New Engl J Med 335:369-76, 1996.
• Kumar A, Eckman JR, Wick, TM: Inhibition of plasma mediated adherence of sickle erythrocytes to microvascular endothelium by conformationally constrained RGD-containing peptides. Am J Hematol 53:92-98, 1996.
• Kumar A, Eckman JR, Swerlick RA, Wick TM: Phorbol ester stimulation increases sickle erythrocyte adherence to endothelium: A novel pathway involving a4b1 integrin receptors on sickle reticulocytes and fibronection. Blood 88:4348-4358, 1996.
• Eckman JR: Leg ulcers in sickle cell disease. Hematol/Oncol Clinics of N America. Charache S, Johnson C, eds., W. B. Saunders Co, Philadelphia. 10:1333-1344, 1996.
• Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP, and Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia: Hydroxyurea and sickle cell anemia. Medicine 75:300-326, 1996.
• Walters MC, Patience M, Leisenring, Buchanan GR, Castro O, Dinndorf P, Davies SC, Dickerhoff R, Eckman JR, et al: Collaborative study of marrow transplantation for sickle cell disease: Aspects specific for transplantation of hemoglobin disorders. Bone Marrow Transplantation 19(2):102-105, 1997.
• Kaslow N, Collins M, Loundy MR, Brown F, Hollins LD, Eckman J: Empirically-validated family interventions for pediatric psychology: sickle cell disease (SCD) as an exemplar. J Pediatr Psychol 22(2):213-227, 1997.
• Platt AF, Eckman JR: Grappling with the sickle cell: diagnosing and managing hemoglobin disorders. Advances for Physician Assistants 5(5)21-24, May 1997.
• Neumayr L. Koshy M, Haberkern C, Earles AN, Bellevue R, Hassell K, Miller S, Black D, Vichinsky E, and the Preoperative Transfusion in Sickle Cell Disease Study Group: Surgery in patients with hemoglobin SC disease. Am J Hematol 57:101-108, 1998.
• Baskins ML, Collins MH, Brown F, Griffith JR, Samuels D, Moody A, Thompson MP, Eckman J, and Kaslow NJ: Psychosocial considerations in sickle cell disease (SCD): The transition from adolescence to young adulthood. J Clin Psychol in Medical Settings 5(3):315-341, 1998.
• Ivers CE, Brown RT, Lambert RG, Hsu L, Eckman J: Family functioning and social support in the adaptation of care givers of children with sickle cell syndromes. J Pediatr Psychol, 23(6):377-388, 1998.
• Brown RT, Lambert R, Donegan JE, Eckman J: Predictors of psychosocial and cognitive adaptation in children with sickle cell syndromes. In Press, J Clin Psychol in Medical Settings, September 1998.
• Collins M, Kaslow N, Doepke K, Eckman J, Johnson M: Psychosocial interventions for children and adolescents with sickle cell disease. In Press, J Black Psychol, 1998.
• Tomer A, Eckman JR, Kasey S, Harker LA: Prothrombotic state in sickle cell disease: direct evidence for in vivo platelet activation, erythrocyte procoagulant activity, and increased plasma markers of thrombotic and fibrinolytic activities. Blood. Submitted for Review, 1998.
• Tomer A, Eckman JR, Kasey S, Connor WE, Clark S, Harker LA: Reduction in pain episodes of sickle cell disease by dietary n-3 fatty acids. New Engl J Med. Submitted for Review, 1998.
• Guasch A, Zayas CF, Eckman JR, Muvalidham K, Zhang W, Elsas LJ: Evidence that microdeletions in the a globin gene protect against the development of sickle cell glomerulopathy. Submitted for Review, 1998.
• Brown RT, Lambert R, Devine D, Baldwin K, Doepke K, Ievers C, Donegan J, Hsu L, Buchanan I, Eckman J: Risk-resistance-adaption model for children with sickle cell syndromes: a test of Wallanders Model. Submitted for Review, 1998.
• Adams RJ, McKie VC, Hsu LL, et al., 1998. Prevention of a First Stroke by Transfusion in Children with Sickle Cell Anemia and Abnormal Results on Transcranial Doppler Ultrasonography. New England J Med 339:5-11.
• Liu X-W, Pierangeli SS, Barker J Wick TM, Hsu LL. 1998. RBC Adhesion to Cremaster Endothelium in Mice with bnormal Hemoglobin is Increased by Topical Endotoxin. Ann of NY Acad Sci 850:391-393.
Monographs, Position Papers, and Guidelines
• S. Panny, A. Davidson, J. Eckman, W.H. Hannon, M.A. Henson, M. Hillard, S. Kling, H. Levy, F.J Meaney, E. McCabe, V. Mordaunt, K. Pass, E. Shapira, B. Therrell, J. Tuerck: Newborn Screening System Guidelines. Prepared by the Council of Regional Networks for Genetic Services, 1990.
• N. Chamberlain, J. Eckman, C. Mitchell, K.B. Nash, K.D. Kramer, B. Cole, D. Nebrig: Sickle Cell…A Resource Guide for Families and Professionals. Compiled by the Psychosocial Research Division of the Duke University Comprehensive Sickle Cell Center. Prepared through the Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Bureau, Genetic Services Branch, 1990.
• J.G. Adams, III, R.M. Baine, J.R. Eckman, S.H. Embury, W.H. Hannon, T.R. Kinney, A. Kutlar, K.A. Pass, C. Reid, M.H. Steinberg, B.L. Therrell: Newborn Screening for Hemoglobinopathies: Program Development and Laboratory Methods. Prepared by the Ad Hoc Newborn Screening Committee and the National Sickle Cell Disease Advisory Committee for the Council of Regional Networks for Genetic Services, 1991.
Abstracts presented at national meetings
• Platt A, Pettigrew T, Benjamin P, Eckman JR: Data transfer in newborn screening by personal computers. Presented at Annual Meeting of NIH National Sickle Cell Disease Program. Boston Sickle Cell Center. April 15, 1986.
• *Platt A, Eckman JR, Lamson P: Total health care for sickle cell patients in a county hospital setting: Is it cost effective? Presented at Annual Meeting of NIH National Sickle Cell Disease Program. Boston Sickle Cell Center. April 15, 1986.
• *Eckman JR, Benjamin P: Sickle cell newborn screening: The Grady experience. Presented at Annual Meeting of NIH National Sickle Cell Disease Program. Boston Sickle Cell Center. April 15, 1986.
• *Eckman JR, Kinney TR, Harris MS: Promotion of newborn sickle cell screening by a TASCS Force. For presentation at American Public Health Association. Las Vegas. September 28- October 2, 1986. Official Program of the 114th Annual meeting of the Amer. Assoc. of Pub Health. p. 50, 1986.
• *Harris MS, Harris HR, Eckman JR: Georgia’s newborn screening program: A system for monitoring and evaluating program efficiency and outcome. For presentation at American Public Health Association. Las Vegas. September 28-October 2, 1986.
• *Allon M, Lawson L, Eckman JR, Delany V, Burke B: Effects of nonsteroidal anti-inflammatory drugs (NSAID) on renal hemodynamics, solute and water handling in sickle cell anemia (SS). American Society of Nephrology. Dec. 1987.
• Grossman BJ, Eckman JR, and Duncan A: Protein C and other vitamin K dependent factor changes in patients with sickle cell anemia. Blood 70:61a, 1987.
• *Bishop R, Robertson J, Eckman JR, Flemming LL: Total hip arthroplasty in patients with a sickle hemoglobinopathy. J Bone and Joint Surg. 1988.
• *Eckman JR, Kinney TR, and Harris MS: Newborn screening for hemoglobinopathies: Facilitation by a TASCS Force. Presented at Annual Meeting of NIH National Sickle Cell Disease Program. Sickle Cell Disease – Current Perspectives. New York Acad Sci April 11-13, 1988.
• *Gilarsky BP, Fajman BJ, Eckman JR, and Taylor AT: Combined 99m-Technetium Methylene Disphosphonate Bone/111-Indium Leukocyte Imaging in Sickle Cell Bone Infarction. Submitted to Radiology Society of North America.
• *Ba’albaki HA, Ghazzal ZMB, Sinyard RD, Eckman JR, Felner JM, and Schlant RC: Cardiac Performance by Echo-Doppler in Adults with Sickle Cell Disease. Submitted to American Heart Association. November 14-17, 1988.
• *Karlstrom EM, Pollard WE, Platt AF, Eckman JR, Abel GG: The characteristics of pain and functioning during sickle cell disease pain crisis. Society of Behavioral Medicine, 10th Annual Scientific Session, February 29-March 1, 1989, p. 151.
• *Bagley B, Barrett D, Zasa M, Platt A, Pollard W, Abel GG, Eckman J, Karlstrom EM: The impact of narcotic analgesic utilization on psychosocial functioning in sickle cell patients. Society of Behavioral Medicine, 10th Annual Scientific Session, February 29-March 1, 1989, P. 151.
• *Eckman JR, Harris MS, Kinney TR: Facilitation of newborn screening for hemoglobinopathies in the Southeastern United States by a TASCS Force. 7th National Neonatal Screening Symposium. New Orleans, November 15-19, 1989.
• *Oyesiku NM, Barlow DL, Eckman JR, Tindall SC, Colohan A, and Tindall G: Intracranial Aneurysms in sickle cell anemia: Clinical features and Pathogenesis. 1st. International Stroke Conference, Kyodo, Japan 1989.
• *Hunter RL, Stack JE, Check IJ, Eckman JR. RHEOTHRX Copolymer enhances sickle cell blood flow in vitro. Blood 74:261a, 1989.
• *Degree DA, D’Souza MJ, Eckman JR, and DeSouza PT. Acetaminophen and antipyrine disposition in normal volunteers and sickle cell anemia patients. Clin Res. in Press.
• *Pollard WE, Platt AF, Eckman JR, Abel GG. The effect of statistical regression on power and statistical conclusion validity in evaluation studies. American Evaluation Association Annual Meeting. San Francisco, Cal. October 19-21, 1989.
• *Oyesiku NM, Barlow DL, Eckman JR, Tindall SC, Colohan ART, Tindall GT: Intracranial Aneurysms in sickle cell anemia: A paradigm for acquired aneurysm formation. Medical Association of Georgia. Georgia Neurosurgical Society. 1989 Annual Meeting.
• Oyesiku NM, Barlow DL, Eckman JR, Tindall SC, Colohan ART, Tindall GT: Intracranial Aneurysms in sickle cell anemia: Clinical features and likely pathogenesis. 15th International Joint Conference on Stroke and Cerebral Circulation. Orlando, Florida. February 15-17, 1990.
• *Eckman JR, Platt A: The Georgia Sickle Cell Center: A comprehensive emergency clinic model. For presentation at the 1990 Annual National Sickle Cell Centers Meetings. San Francisco, California. May 16-18, 1990.
• *Platt A, Eckman JR: Frequency of presentation for sickle cell pain crisis: A five year summary. For presentation at the Annual National Sickle Cell Centers Meetings. San Francisco, California. May 16-18, 1990.
• *Platt A, Eckman JR: The utilization of physician assistants and protocols for the management of sickle cell syndromes. For presentation at the Annual National Sickle Cell Centers Meetings. San Francisco, California. May 16-18, 1990.
• *Eckman JR, Platt A, Oyesiku N: Subarachnoid hemorrhage in patients with sickle cell syndromes: A ten year experience. For presentation at the Annual National Sickle Cell Centers Meetings. San Francisco, California. May 16-18, 1990.
• *Howard J, Williams N, Eckman J, Platt A: A systematic approach to the management of sickle cell leg ulcers. For presentation at the Annual National Sickle Cell Centers Meetings. San Francisco, California. May 16-18, 1990.
• *Mbonzo JR, Eckman JR, Platt AF: The issue of iatrogenic addiction and pain control in sickle cell disease. For presentation at the Annual National Sickle Cell Centers Meetings. San Francisco, California. May 16-18, 1990.
• *Buchanan ID, McKean LP, Eckman LP, Smith TF: Response to bronchodilators in children with sickle cell disease. For presentation at the Annual National Sickle Cell Centers Meetings. San Francisco, California. May 16-18, 1990.
• *Brittain HA, Eckman JR, Wick TM: Sickle erythrocyte adhesion to endothelial cells: A potential modulator of microvascular occlusion in sickle cell disease. First World Congress of Biomechanics. Univ. Calf. S. D. September 30-October 4, 1990.
• *Wick TM, Brittain HA, Eckman JR: Sickle erythrocyte adhesion to microvascular endothelial cells is qualitatively different from adhesion to large vessel (umbilical vein) endothelial cells. 62nd Annual Meeting of The Society of Rheology. Santa Fe, New Mexico. October 21-25, 1990.
• *Brittain HA, Eckman JR, Wick TM: Plasma-mediated adhesion of sickle red cells is due to both sickle plasma and red cell factors, and is quantitatively different to large and micro-vessel endothelial cells under physiologic flow. American Institute of Chemical Engineers 1990 Meeting. Chicago, Illinois. November 11-16, 1990.
• *Papadea C, Abbott K, Platt AF, Eckman JR: Comparison of abnormal hemoglobins for newborn screening using liquid and dried blood. 8th Annual Neonatal Screening Symposium and 21st Birth Defect Symposium. Saratoga Springs, New York. January 29- February 2, 1991.
• *Eckman JR: NIH document, Newborn Screening for Hemoglobinopathies: Program Development and Laboratory Methods. O-40. 8th Annual Neonatal Screening Symposium and 21st Birth Defect symposium. Saratoga Springs, New York. January 29-February 2, 1991.
• *Wick TM, Brittain HA, Eckman JR: Abnormal adhesion of sickle erythrocytes to human microvascular endothelial cells in due to red cell factors and collagen-binding plasma proteins. Annual N.I.H. Sickle Cell Centers and Clinics Meeting. Mobile, Alabama. March 24-26, 1991.
• *Wick TM, Brittain HA, Eckman JR: Sickle erythrocyte adherence to microvascular endothelial cells under shear flow conditions: Requirements for both plasma and erythrocyte abnormalities and its relevance to sickle cell vaso-occlusive crises. Annual Meeting of the N.I.H. Sickle Cell Centers and Clinics Meeting. Mobile, Alabama. March 24-26, 1991.
• *Brittain HA, Wick TM, Eckman JR: Abnormal adhesion of sickle red blood cells to human microvascular endothelial cells: A potential role for the plasma milieu in the initiation of vaso-occlusion. Annals of Biomedical Engineering. 19:580, 1991. Biomedical Engineering Society Meeting. Charlottesville, Virginia. October 1991.
• *Noonan AS, Murray R, Lin-Fu J, Eckman J, Hunter-Grant C: Newborn screening for sickle cell disease and other hemoglobinopathies: Where do we go from here? Panel. American Public Health Association Annual Meeting. Atlanta, Georgia. November 10-14, 1991.
• *Brittain HA, Wick TM, Eckman JR: Adhesion of sickle red blood cells to human microvascular endothelial cells under venous flow conditions. American Institute of Chemical Engineers. Los Angeles, California. November 17-22, 1991.
• *Platt A and Eckman J: Sickle cell patient management simulations using PC computers. 1992 Annual National Sickle Cell Centers Meeting, Nashville, Tennessee. March 16-20, 1992.
• *Hunter J, Platt A, Eckman J: Sensitivity of diagnostic studies in sickle cell patients with subarachnoid hemorrhage or cerebral aneurysms. 1992 Annual National Sickle Cell Centers Meeting, Nashville, Tennessee. March 16-20, 1992.
• *Handley-Palmer S, Platt A, Eckman J: Pulse oximetry measurements in treatment of sickle pain episodes. 1992 Annual National Sickle Cell Centers Meeting, Nashville, Tennessee. March 16-20, 1992.
• *Mbonzo JR, Platt A, Eckman J: The use of non-narcotics in sickle cell pain management. 1992 Annual National Sickle Cell Centers Meeting, Nashville, Tennessee. March 16-20, 1992.
• *Brown RT, Buchanan I, Baldwin K, Eckman J, Kaslow NJ: Predictors of adjustment in youth with sickle cell disease. In M. Lopez (Chair, Coping Across the Life Span. Presented at the annual meeting of the Society of Behavioral Medicine. New York, NY, March,1992.
• *Wick TM, Brittain HA, Howard R, Eckman JR: Thrombospondin from activated platelets promote sickle erythrocyte adherence to human microvascular endothelial cells via CD36 and integrin receptors. NATO Advanced Studies Institute, Vascular Endothelium: Physiological Basis of Clinical Problems II. Rhodes, Greece. June 1992.
• *Wick TM, Brittain HA, Eckman JR: Thrombospondin from activated platelets media sickle red cell adhesion to microvascular endothelium. 1992 Annual Fall Meeting of the Biomedical Engineering Society. Salt Lake City, Utah. October 1992.
• *Brittain HA, Wick TM, Eckman JR: Thrombospondin from activated platelets medical sickle red cell adhesion to microvascular endothelium: A potential role for intravascular coagulation in sickle cell anemia. 1992 Annual Meeting of the American Institute of Chemical Engineers. Miami, Florida. November 1992.
• *Wick TM, Brittain HA, Swerlick RA, Eckman JR: Thrombospondin from activated platelets promotes sickle erythrocyte adherence to endothelium: A potential role for platelet activation in sickle cell vaso-occlusion. Blood 80(10 Suppl 1):76a. Presented at the American Society of Hematology 34th Annual Meeting, Anaheim, California. December 4-8, 1992.
• *Wick TM, Eckman JR, Kumar A, Jeitler M, Swerlick RA: Reticulocytes from patients with sickle cell anemia express the a4/1b1 integrin complex and bind to TNF-a activated endothelial cells via a VCAM-1/a1b4 dependant mechanism. Blood 80(10 Suppl 1):11a. Presented at the American Society of Hematology 34th Annual Meeting, Anaheim, California. December 4-8, 1992.
• *Tomer A, Eckman JR, Vroon DH: Platelet activation and procoagulant activity in sickle cell disease. Blood 80(10 Suppl 1):11a, 1992. Presented at the American Society of Hematology 34 Annual Meeting, Anaheim, California. December 4-8, 1992.
• *Hassell KL, Eckman JR, Lane PA: Acute multi-organ failure syndrome: A potentially catastrophic complication of severe sickle cell pain episodes. Blood 80(10 Suppl 1):9a, 1992. Presented at the American Society of Hematology 34th Annual Meeting, Anaheim, California. December 4-8, 1992.
• *Eckman JR, Papadea C, Platt AF, Kuehnert R: Liquid cord blood and dried filter paper spots: A comparison of programmatic and laboratory performance in newborn hemoglobinopathy screening. Presented at the 1993 Annual National Sickle Cell Centers Meeting, Philadelphia, PA. May 22-25, 1993.
• *Platt A and Eckman J: The cost and benefits of operating a 24 hour comprehensive sickle cell center. Presented at the 1993 Annual National Sickle Cell Centers Meeting, Philadelphia, PA. May 22-25, 1993.
• *Hunter JH, Eckman JR, Platt AF: Evaluation of headaches in patients with sickle cell syndromes. Presented at the 1993 Annual National Sickle Cell Centers Meeting, Philadelphia, PA. May 22-25, 1993.
• *Platt AF, Eckman JR: The establishment of regional patient databases with 24 hour clinical phone line for sickle cell provider support. Presented at the 1993 Annual National Sickle Cell Centers Meeting, Philadelphia, PA. May 22-25, 1993.
• *Platt AF, Eckman JR: Sickle cell provider training and certification. Presented at the 1993 Annual National Sickle Cell Centers Meeting, Philadelphia, PA. May 22-25, 1993.
• *Wick TM, Kumar A, JR, Swerlick RA: Sickle reticulocytes express the a4b1 integrin complex and bind to TNF-a activated endothelial cell via a VCAM-1a4b1 dependant mechanism. Presented at the 1993 Annual National Sickle Cell Centers Meeting, Philadelphia, PA. May 22-25, 1993.
• *Kumar A, Eckman JR, Wick TM: Plasma enhancement of sickle red blood cell (RPB) adherence to microvascular endothelial cells (MEC) mediated by integrin receptors can be inhibited by conformationally constrained RGD peptides. Presented at the Annual Society of Hematology. St. Louis, MO, December 4-7, 1993. Blood 82S, 1395, 1993.
• *Smolinski PA, Offermann MK, Eckman JR: Synthetic double-stranded RNA increases adherence of sickle red blood cells (SRBC) to human umbilical vein endothelial cells (HUVEC) via a4b1 – Vascular cell adhesion molecule-1 (VCAM-1) pathway. Blood 82S:352a, 1993. Presented at the Annual Society of Hematology. St. Louis, MO, December 4-7, 1993.
• *Wick TM, Brown MD, Eckman JR: Sickle red blood cells (RBC) induce expression of cell adhesion molecules on human umbilical vein endothelial cells (HUVEC). Blood 82S:352a, 1993. Presented at the Annual Society of Hematology. St. Louis, MO, December 4-7, 1993.
• *Kumar A, Eckman JR, Swerlick RA, Wick TM: Stimulation of sickle erythrocytes with phorbol ester promotes adherence to endothelium: a potential role for activated VLA-4 (a4b1) on sickle reticulocytes. Blood 82S:352a, 1993. Presented at the Annual Society of Hematology. St. Louis, MO, December 4-7, 1993.
• *Sharpe J, Brown RT, Thompson N, Buchanan I, Eckman JR: Predictors of adaptive behavior in children with sickle cell disease. Presented at the 1994 Annual Sickle Cell Centers Meeting. New York, NY, March 23-26,1994.
• *Brown RT, Eckman J, Baldwin K, Kaslow NJ, Buchanan I, Dingle AD: Predictors of adaptive behavior in children with sickle cell disease. Presented at the 1994 Annual Sickle Cell Center Meeting, New York, NY, March 23-26, 1994.
• *Kumar A, Eckman JR, Swerlick RA, Wick TM: Phorbol ester treatment of sickle erythrocytes promotes adherence to endothelium: Evidence for the activation of a4b1 on sickle reticulocytes and involvement of fibronectin. Presented at the 1994 Annual Fall Meeting of Biomedical Engineering Society, Tempe, AZ, October 14-16, 1994.
• *Smolinski PA, Offermann MK, Eckman JR, Wick TM: Double stranded RNA mediates sickle erythrocyte a4b1-endothelial VCAM-1 adhesion: A potential role for viral infection in sickle cell vaso-occlusion. Presented at the 1994 Annual Fall Meeting of the Biomedical Engineering Society, Tempe, AZ, October 14-16, 1994.
• *Brown MD, Eckman JR, Wick TM: Endothelial activation upon incubation with sickle cells. Annals of Biomedical Engineering 22(suppl 1):33, 1994. Presented at the 1994 Annual Biomedical Engineering Society, Tempe, AZ, October 14-16, 1994.
• *Kumar A, Eckman JR, Swerlick RA, Wick TM: Sickle erythrocytes stimulated with phorbol ester adhere to endothelium via activated a4b1 integrin on sickle reticulocytes and fibronectin on endothelium. Presented at the 36th Annual American Society of Hematology, Nashville, TN, December 2-6, 1994.
• *Smolinski PA, Eckman JR, Wick TM: In vitro comparison of known mechanisms of sickle erythrocyte adherence to endothelium: Biophysical studies to predict the relative importance of competing adherence pathways in vivo. Presented at the 36th Annual American Society of Hematology, Nashville, TN, December 2-6, 1994.
• *Sherrill AW, Williams JJ, Eckman JR, Wick TM, Nerem RM: Short-term contact with sickle erythrocytes inhibits shear-induced elongation of arterial endothelium. Presented at the 36th Annual American Society of Hematology, Nashville, TN, December 2-6, 1994.
• *Tomer A, Harker LA, Eckman JR: Circulating platelets and red cells promote in vivo thrombogenic activity in sickle cell disease. Presented at the 36th Annual American Society of Hematology, Nashville, TN, December 2-6, 1994.
• Brown MD, Eckman JR, Wick TM: Modulation of endothelial cell adhesion molecule expression by sickle cells is mediated through the production of a soluble factor. Presented at the 20th Annual of the National Sickle Cell Program, Boston, MA, March 18-21, 1995.
• *Kumar A, Eckman JR, Swerlick RA, Wick TM: Phorbol ester stimulates sickle erythrocytes to adhere to vascular endothelium: A novel pathway involving a4b1 and fibronectin. Presented at the 20th Annual Meetings of the National Sickle Cell Program, Boston, MA, March 18-21, 1995.
• Smolinski PA, Eckman JR, Wick TM: Biophysical studies to predict the relative tenacity of receptor mediated sickle-erythrocyte adherence pathways in vitro: Implications for physiological significance in the onset of vascular occlusion in sickle cell anemia. Presented at the 20th Annual Meetings of the National Sickle Cell Program, Boston, MA, March 18-21, 1995.
• Margolis G, Brown RT, Baldwin K, Doepke K, Casey R, Eckman J: Magnetic resonance imaging and neurophysiological evaluation in children with sickle cell syndrome (SCD). Presented at the 20th Annual Meetings of the National Sickle Cell Program, Boston, MA, March 18-21, 1995.
• Platt A, Eckman J: Multimedia computer based sickle cell tutorial for medical personnel. Presented at the 20th Annual of the National Sickle Cell Program, Boston, MA, March 18-21, 1995.
• Tomer A, Kasey S, Harker LA, Eckman JR: Are sickle pain episodes thrombotic events? In vivo evidence for platelet and red cell procoagulant activity. Presented at the 20th Annual Meetings of the National Sickle Cell Program, Boston, MA, March 18-21, 1995.
• Smolinski PA, Eckman JR, Wick TM: Increased tenacity of sickle erythrocyte-endothelial cell adherence by involvement of multiple receptor-ligand interactions. Presented at the 37th Annual American Society of Hematology, Seattle, WA, December 1-5, 1995.
• Tomer A, Harker LA, Kasey S, Eckman JR: Reduced predisposition to thrombosis in sickle cell disease (SCD) patients treated with dietary n-3 fatty acids (n-3FA). Presented at the 37th Annual American Society of Hematology, Seattle, WA, December 1-5, 1995.
• Platt A, Eckman: Multimedia computer based sickle cell tutorial for patients and families. Presented at the 21th Annual Meetings of the National Sickle Cell Program, Mobile, AL. March 6-9, 1996.
• *Smolinski PA, Eckman JR, Wick TM: Biophysics of sickle erythrocyte-endothelial cell adherence Presented at the Biomedical Engineering Society 1996 Annual Fall Meeting, October 1996.
• McNaull SA, Eckman, JR, Wick TM: Sickle red blood cell adherence to vascular endothelium is more tenacious in confined flow channels. Presented at 38th Annual American Society of Hematology, Orlando, Florida, December 6-10, 1996.
• Montes, RAO, Eckman JR, Wick TM: Continuous recirculating contact enhances adhesion of sickle red blood cells to endothelial cells. Presented at 38th Annual American Society of Hematology, Orlando, Florida, December 6-10, 1996.
• Vassy WM, Eckman JR, Wick TM: Inhibition of plasma-mediated sickle erythrocyte adherence to microvascular endothelium by ploxymer compounds. Presented at 38th Annual American Society of Hematology, Orlando, Florida, December 6-10, 1996.
• *Smolinski PA, Eckman JR, Wick TM: Tenacity of sickle red blood cell (SRBC)-endothelial cell (EC) adherence is augmented under hemodynamic shear and by involvement of multiple adhesion pathway. Presented at 38th Annual American Society of Hematology, Orlando, Florida, December 6-10, 1996.
• *Eckman, JR, Platt AF, Palmer SH: Comprehensive primary care in sickle cell syndromes: a managed care model that works. Presented at a symposium at the 25th Annual Meetings of the NIH Sickle Cell Program, Washington, D.C., September 15-20, 1997.
• *Platt A, Eckman R: Multimedia teaching center for educating patients and professionals about sickle cell disease. Presented at the 25th Annual Meetings of the NIH Sickle Cell Program, Washington, D.C., September 15-20, 1997.
• *Platt AF, Mbonzo R, Eckman R: The use of parenteral nalbuphine (Nubain) to treat adults with sickle pain episodes. Presented at the 25th Annual Meetings of the NIH Sickle Cell Program, Washington, D.C., September 15-20, 1997.
• *Platt A, Eckman R: Rapid pain assessment using a multidimensional pain meter. Poster presentation at the 25th Annual Meetings of the NIH Sickle Cell Program, Washington, D.C., September 15-20, 1997.
• Adamkiewicz TV, Hsu LL, Rubinstein P Kaplan CA, Eckman JR, Yeager AM: Feasibility of identification of unrelated placental/umbilical cord blood cell (PUBC) units for transplantation in patients (PTS) with high-risk sickle cell disease (SCD). Poster presentation at the 40th Annual Meeting of the American Society of Hematology, Miami Beach, Florida, December 4-8, 1998
• Asakura T, Williams PV, Asakura K, Wang YJ, Reilly MP, Hsu LL, Schwartz E,Ohene-Frempong K, Ballas SK, Eaton WA. Image analysis of erythrocytes in venous blood of SS, SC and S?-thalassemia blood and in blood from transgenic mice which produce human sickle hemoglobin. Presented at American Society of Hematology meeting, December, 1994, Nashville. Blood 84(10, Suppl. 1):406a. 1994.
• Hsu LL, Reilly MP, Asakura TA. Administration of bepridil in vivo decreases dense cell formation in ransgenic mice expressing human sickle hemoglobin – implications for treatment of sickle cell disease. Presented at American Society of Hematology meeting, December 1994, Nashville. Blood 84(10, Suppl. 1):410a. 1994.
• Hsu LL, Semenza GL, Cargile RD, Reilly MP, Asakura T. A transgenic mouse model of hyperviscosity in sickle cell disease. Presented at the 20th Annual Meeting – National Sickle Cell Program, March 1995, Boston. Abstract 34.
• Hsu, L., Semenza GL, Cargile RD, Reilly6 MP, Asakura T (1995). Administration of Bepridil in vivo ecreases dense cell formation in transgenic mice expressing human HbS – implications for treatment of sickle cell disease. J Invest Med 43(1, suppl 1):62a. 1995.
• Hsu, L., Brown LAS, Asakura, T. Aguayo SM (1996). “Transgenic mice expressing human hemoglobin S are sensitive to pulmonary insult by oleic acid.” J Invest Med 44(1):SSPR 36A.
• Hsu, L., Cargile RD, Reilly MP, Luthra H, Asakura T (1996). Effects of bepridil on erythrocyte hydration and sickle morphology in transgenic mice expressing HbS. 21st Meeting of the National Sickle Cell Disease Program, Mobile, Alabama, March 6-9, 1996.
• Hsu, L., Brown LAS, Asakura T, Aguayo SM (1996). Oleic acid acute lung injury in mice as a model for ickle acute chest syndrome. 21st Meeting of the National Sickle Cell Disease Program, Mobile, Alabama, March 6-9, 1996.
• Benaroch, R., Hsu LL (1996). Jehovah’s Witnesses with sickle cell aplastic crises and hemoglobin nadirs of 3.6 and 2.0 gm/dL managed without transfusion. 21st. Meeting of the National Sickle Cell Disease Program, Mobile, Alabama, March 6-9, 1996.
• Collins M, Brown F, Loundry M, Dickman L, Hsu L, Eckman J, Kaslow N Challenges Implementing Psychosocial Interventions with Pediatric Sickle Cell Patients. Presented at 20th Meeting of National Sickle Cell Disease Program, March 6-9, 1996.
• Adams RJ, Brambilla D, for the STOP Investigators. Stroke Prevention Trial in Sickle Cell Anemia: “STOP.” Presented at 20th Meeting of National Sickle Cell Disease Program, March 6-9, 1996.
• Hsu, LL, Brown LAS, Asakura T, Aguayo SM. Oleic Acid Acute Lung Injury In Mice As A Model For Sickle Acute Chest Syndrome. Presented at American Thoracic Society, May, 1996.
• Hsu LL, Dillehay D, Brown LAS, Cargile RD, Asakura T, Aguayo SM, Effect of oleic acid on transgenic mice expressing human HbS – toward an animal model for sickle acute chest syndrome. Blood 88(10, Suppl 1):
• Hsu LL, Wick TM, Burke JR, Kasey S, Tomer A, Cargile RD, Swerlick R. Reticulocytes from beta-thalassemic mice express VLA-4 in vivo and bind to microvascular endothelial cells under shear stress. Blood 88(10, Suppl 1):9
• Liu, XW, Pierangeli, SS, Barker, J, Wick, TM, Hsu, LL (1997) “Erythrocyte adhesion to cremaster endothelium in mice with abnormal hemoglobin is increased by topical endotoxin.” Blood 90(10 Suppl 1):Abstract 1960.
• Hsu, LL, McDermott, T, Aguayo, SM (1997). “Transgenic HbS mouse neutrophils in increased susceptibility to acute lung injury – implications for sickle acute chest syndrome.” Blood 90(10 Suppl 1): Abstract 537.
Books and Book Chapters
• Eckman JR: Anemia Due to Decreased Production of Erythrocytes. Current Diagnosis, 7th Edition. R. Conn, ed, 1984.
• Eckman JR and Platt AF: Problem Oriented Management of Sickle Syndromes. Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Bureau, Genetic Services Branch, Rockville, Maryland, 1991.
• Eckman JR: Hemochromatosis. Medicine for the Practicing Physician, 2nd Edition. J Willis Hurst, ed. Butterworths, Stoneham, Mass. pp. 787-789. 1988.
• Eckman JR: Acquired autoimmune hemolytic anemia. Medicine for the Practicing Physician, 2nd Edition, J Willis Hurst, ed. Butterworths, Stoneham, Mass. pp. 767-769, 1988.
• Eckman JR: Hemoglobinopathies. Medicine for the Practicing Physician, 2nd Edition, J Willis Hurst, ed. Butterworths, Stoneham, Mass. pp. 769-771, 1988.
• Eckman JR: Iron deficiency anemia. Medicine for the Practicing Physician, 2nd Edition, J Willis Hurst, ed. Butterworths, Stoneham, Mass. pp. 749-751, 1988.
• Eckman JR: Sickle Cell Anemia. Medicine for the Practicing Physician, 2nd Edition, J Willis Hurst, ed. Butterworths, Stoneham, Mass. pp. 772-774, 1988.
• Eckman JR: Thalassemias. Medicine for the Practicing Physician, 2nd Edition, J Willis Hurst, ed. Butterworths, Stoneham, Mass. 752-754, 1988.
• Eckman JR: Acquired autoimmune hemolytic anemia. Criteria for Diagnosis, J Willis Hurst, ed. Butterworths, Stoneham, Mass. p. 263, 1989.
• Eckman JR: Hemoglobinopathies. Criteria for Diagnosis, J. Willis Hurst, ed. Butterworths, Stoneham, Mass. p. 263, 1989.
• Eckman JR: Iron deficiency anemia. Criteria for Diagnosis, J. Willis Hurst, ed. Butterworths, Stoneham, Mass. p. 258, 1989.
• Eckman JR: Sickle Cell Anemia. Criteria for Diagnosis, J. Willis Hurst, ed. Butterworths, Stoneham, Mass. pp. 264, 1989.
• Eckman JR: Thalassemias. Criteria for Diagnosis, J. Willis Hurst, ed. Butterworths, Stoneham, Mass. p. 259, 1989.
• Eckman JR: Hemochromatosis. Criteria for Diagnosis, J. Willis Hurst, ed. Butterworths, Stoneham, Mass. p. 270, 1989.
• Eckman JR: Anemia Due to Decreased Production of Erythrocytes. Current Diagnosis, 8th Edition. R. Conn, ed. pp. 523-527, 1989.
• Eckman JR: Disorders of Red Cells. Internal Medicine: A Board Review. Drs. Kokko, Stein, and Walker eds., Science Thru Media, Inc. New York. 1987, 1989, 1991-1994.
• Adams JG, Baine RM, Eckman JR, et al. Newborn Screening for Hemoglobinopathies: Program Development and Laboratory Methods. Drs. M.H. Steinberg & C.D. Reed Eds. N.I.H. Bethesda. 1990.
• Eckman JR: Acquired autoimmune hemolytic anemia. Medicine for the Practicing Physician, 3rd Edition, J Willis Hurst, ed. Butterworths, Stoneham, Mass. pp. 862-865, 1992.
• Eckman JR: Hemoglobinopathies. Medicine for the Practicing Physician, 3rd Edition, J Willis Hurst, ed. Butterworths, Stoneham, Mass. pp. 865-867, 1992.
• Eckman JR: Iron deficiency anemia. Medicine for the Practicing Physician, 3rd Edition, J Willis Hurst, ed. Butterworths, Stoneham, Mass. pp. 846-848, 1992.
• Eckman JR: Sickle Cell Anemia. Medicine for the Practicing Physician, 3rd Edition, J Willis Hurst, ed. Butterworths, Stoneham, Mass. pp. 867-870, 1992.
• Eckman JR: Thalassemias. Medicine for the Practicing Physician, 2nd Edition, J Willis Hurst, ed. Butterworths, Stoneham, Mass. pp. 848-851, 1992.
• Eckman JR: Hemochromatosis. Medicine for the Practicing Physician, 2nd Edition, J Willis Hurst, ed. Butterworths, Stoneham, Mass. pp. 882-884, 1992.
• Eckman JR: Disorders of Red Cells. Internal Medicine: Board Review – Recent Advances. Science-Thru-Media, New York. 1981, 1984, 1986, 1988, 1992.
• Eckman JR: Genetics for the Internist. Internal Medicine: Board Review – Recent Advances. Science-Thru-Media, New York. 1992.
• Eckman JR: Neonatal Screening. The Sickle Hemoglobinopathies: Science and Medicine. Embury SH, Hebbel RP, Narla M, Steinberg MH, eds. Ravin Press. New York, pp. 509-515, 1994.
• Eckman JR: Disorders of Red Cells. Medical Management of the Surgical Patient. Lubin MF, Walker HK, Smith RB, eds. J.B. Lippincott Company. Philadelphia, pp. 189-197, 1994.
• Phillips G, Eckman JR, Hebbel RP: Leg ulcers and myofacial syndromes. The Sickle Hemoglobinopathies: Science and Medicine. Embury SH, Hebbel RP, Narla M, Steinberg MH eds. Ravin Press. New York. pp. 681-688, 1994.
• Eckman JR: The Liver and Hematopoiesis. Hepatology: A Textbook of Liver Disease, 3rd Edition. Zakim D and Boyer T, eds. W. B. Saunders Co., Philadelphia, pp. 685-690, 1996.
• Eckman JR: Hemochromatosis. Medicine for the Practicing Physician, 4th Edition. J Willis Hurst, ed. Appleton & Lange, Norwalk, CT, pp. 924-926, 1996.
• Eckman JR: Newborn Screening for Hemoglobinopathies. Disorders of Hemoglobin. Forget BG, Higgs DR, Nagel RL, and Steinberg MH, eds. Cambridge University Press, Cambridge, U.K. Submitted for publication, December 1998.
